Browsing Tag
SEQUOIA-HCM
2 posts
Cytokinetics stock skyrockets 40% as ESC 2025 data positions aficamten to challenge beta-blockers in HCM
Cytokinetics shares surged 40% after new ESC 2025 data showed aficamten's superiority to metoprolol in HCM. Is FDA approval now inevitable?
September 3, 2025
Sanofi strengthens cardiovascular portfolio with Aficamten rights in Greater China
Cytokinetics, Incorporated (NASDAQ: CYTK) saw its shares climb by 4.8% after announcing a landmark agreement with Sanofi (NASDAQ:…
December 23, 2024